Nasdaq exas.

In recent trading, shares of EXACT Sciences Corp. (Symbol: EXAS) have crossed above the average analyst 12-month target price of $88.50, changing hands for $91.09/share. When a stock reaches the ...

Nasdaq exas. Things To Know About Nasdaq exas.

A market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...Nov 20, 2023 · Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 92.96 0.00 0.00%. The 17 analysts offering 1 year price forecasts for EXAS have a max estimate of — and a min estimate of —.Nov 30, 2023 · The public float for EXAS is 179.16M, and currently, short sellers hold a 4.07% ratio of that floaft. The average trading volume of EXAS on November 30, 2023 was 1.42M shares. EXAS) stock’s latest price update. Exact Sciences Corp. (NASDAQ: EXAS)’s stock price has increased by 0.14 compared to its previous closing price of 64.97.

Feb 10, 2023 · As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ... Exact Sciences (NASDAQ: EXAS) is a biotech stock leveraging AI. The company also comprises the largest holding in Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) at 10.38% total weight.

Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain. Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders might be concerned after seeing the share price ...

EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Exact Sciences (EXAS) closed the most recent trading day at $42.47, moving +0.14% from the previous trading session. This change lagged the S&P 500's 6% gain on the day. Meanwhile, the Dow gained ...... Back to EXAS Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …WebExact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...

Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM ESTWeb

Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report) was up 7.6% during trading on Friday . The company traded as high as $66.06 and last traded at $65.84. Approximately 1,116,388 shares changed hands during trading, a decline of 40% from the average daily volume of 1,860,572 shares. The stock had previously closed at $61.17.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted).As of today (2023-11-13), Exact Sciences's share price is $59.44.Exact Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.59.Therefore, Exact Sciences's …TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Nov 2, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. ... Exact Sciences (EXAS 4.73%) Q3 2023 Earnings Call Nov 01, 2023, 5:00 p.m. ET. Contents: Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM ESTWebEXACT SCIENCES CORP ( EXAS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...

Texas Instruments Incorporated Common Stock (TXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 64.83 -0.23 (-0.35%) As of 12:06PM EST. Market …WebExact Sciences Corp (NASDAQ:EXAS) Intrinsic Valuation. Check if EXAS is overvalued or undervalued under the bear, base, and bull scenarios of the company's ...MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.

Feb 27, 2018 · ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona. Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...

Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...On March 10, 2020, I opined that Exact Sciences (NASDAQ:EXAS) had solid potential but was suffering because it had announced a public offering of $850 million (upped to 1 billion) of 0.3750% ...Board. Exact Sciences to participate in November investor conferences. November 01 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ...Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... 1. Exact Sciences. Exact Sciences' goal is to eradicate cancer. Perhaps that's too optimistic, but the company could play a role in reducing cancer deaths through its diagnostic solutions.35,260.96. +172.67. 【日本経済新聞】エグザクト・サイエンシズ/EXACT Sciences [EXAS] の株価、チャート、業績推移、会社概要、ニュースなど米国株投資や ...17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...

Feb 21, 2023 · Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...

EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.

Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001.Find the latest SEC Filings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Dec 4, 2023 · Exact Sciences (NASDAQ:EXAS) has a recorded net income of -$623.51 million. EXAS has generated -$1.59 earnings per share over the last four quarters. What is Exact Sciences's EPS forecast for next year? EXAS missed the consensus earnings per share in the 1st calendar quarter of 2020 by -5.26%. Zacks Investment Research reports that the 2020 Price to Earnings ratio for EXAS is -92.27 vs. an ...To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.Oct 13, 2022 01:52PM EDT. Investors in EXACT Sciences Corp. (Symbol: EXAS) saw new options begin trading today, for the December 2nd expiration. At Stock Options Channel, our YieldBoost formula ...Exact Sciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 28.7% per year. This section of the company report contains some beta features. How Exact Sciences makes and spends money.EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 92.96 0.00 0.00%. The 17 analysts offering 1 year price forecasts for EXAS have a max estimate of — and a min estimate of —.Exact Sciences Stock Price, News & Analysis (NASDAQ:EXAS) $67.03 +3.03 (+4.73%) (As of 12/1/2023 ET) Compare Today's Range $62.76 $67.03 50-Day Range …Web2 Nov 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...Exact Sciences (EXAS) closed the most recent trading day at $60.68, moving -0.49% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.77%. Meanwhile, the ...Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The …Web

MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will ...1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Apr 27, 2022 3:33PM EDT. A mong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Qualcomm Inc (Symbol: QCOM), where a total of 80,465 ...Instagram:https://instagram. nasdaq prtsus stock market holidays 2023ucare vs blue plusjohnson and johnson dividends EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... how to purchase amc stockis beagle legit 401k 1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.Exact Sciences Corporation. Add. exactsciences.com · $EXASNASDAQ. $93.37. Exact Sciences Corporation provides cancer screening and diagnostic test products in ... wfpax MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473 .8 million ...Exact Sciences Corporation Common Stock (EXAS) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.